ArticleInfection and immunity1999
Towards a Taenia solium cysticercosis vaccine: an epitope shared by Taenia crassiceps and Taenia solium protects mice against experimental cysticercosis.
Article in Infection and immunity, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 92 citations in OpenAlex.
- Article
- The hidden threat of cysticercosis: A neglected public health problem.Open veterinary journal · 2025Review
- Innate Immune Response to Helminth Infections.Advances in experimental medicine and biology · 2025Review
- Exploring the Mechanisms Underlying Cellular Uptake and Activation of Dendritic Cells by the GK-1 Peptide.ACS omega · 2024Article
- Suppression of the growth and metastasis of mouse melanoma byFrontiers in immunology · 2024Article
- GK-1 Induces Oxidative Stress, Mitochondrial Dysfunction, Decreased Membrane Potential, and Impaired Autophagy Flux in a Mouse Model of Breast Cancer.Antioxidants (Basel, Switzerland) · 2022Article
- Mimotope-based antigens as potential vaccine candidates in experimental murine cysticercosis.Parasitology · 2020Article
- An AMA1/MSP1Molecular biotechnology · 2020Article
- Scorpion Venom: Detriments and Benefits.Biomedicines · 2020Review
- A self-aggregating peptide: implications for the development of thermostable vaccine candidates.BMC biotechnology · 2020Article
- Anti-GK1 antibodies damage Taenia crassiceps cysticerci through complement activation.Parasitology research · 2018Article
- Experimental and Theoretical Approaches To Investigate the Immunogenicity of Taenia solium-Derived KE7 Antigen.Infection and immunity · 2017Article
- Article
- Article
- Taenia solium: Development of an Experimental Model of Porcine Neurocysticercosis.PLoS neglected tropical diseases · 2015Article
- Analysis of the expression of cytoskeletal proteins of Taenia crassiceps ORF strain cysticerci (Cestoda).Parasitology research · 2014Article
- The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model.Cancer biotherapy & radiopharmaceuticals · 2013Article
- Immunoregulation by Taenia crassiceps and its antigens.BioMed research international · 2013Article
- Heterologous prime-boost oral immunization with GK-1 peptide from Taenia crassiceps cysticerci induces protective immunity.Clinical and vaccine immunology : CVI · 2011Article
- Immunoinformatics prediction of linear epitopes from Taenia solium TSOL18.Bioinformation · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Taenia crassiceps recombinant antigen KETc7 has been shown to be effective as a vaccine against experimental murine cysticercosis, a laboratory model used to test potentially promising molecules against porcine Taenia solium cysticercosis. Based on the deduced amino acid sequence of this proline-rich polypeptide, three fragments, GK-1, GK-2, and GK-3, were chemically synthesized in linear form. Of the three peptides, only GK-1 induced sterile protection against T. crassiceps cysticercosis in 40 to 70% of BALB/cAnN male mice. GK-1 is an 18-amino-acid peptide which contains at least one B-cell epitope, as demonstrated by its ability to induce an antibody response to the peptide and T. crassiceps antigen without need of a carrier protein. Immunofluorescence studies revealed that anti-GK1 antibodies strongly react with the native protein in the tegument of T. crassiceps and also with anatomical structures of T. solium eggs, oncospheres, cysticercus, and tapeworm. GK-1 also contains at least one T-cell epitope, capable of stimulating the proliferation of CD8(+) and to a lower extent CD4(+) T cells primed either with the free peptide or T. crassiceps total antigen. The supernatant of the stimulated cells contained high levels of gamma interferon and low levels of interleukin-4. Similar results were obtained with T cells tested for intracellular cytokine production, an indication of the peptide's capacity to induce an inflammatory response. The remarkable protection induced by GK-1 immunization, its physicochemical properties, and its presence in all developmental stages of T. solium point to this synthetic peptide as a strong candidate in the construction of a synthetic vaccine against T. solium pig cysticercosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.